EVRY, France–(BUSINESS WIRE)–These results are very encouraging and show the potential of the product with data rarely seen in neuromuscular diseases at such an early stage.
Atamyo Therapeutics Presents Promising Results in the First Patients Treated With Its ATA-200 Gene Therapy in the Clinical Trial Targeting LGMD-R5 Limb-girdle Muscular Dystrophy
